Literature DB >> 21690264

Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals.

Jette Peters1, Wiebke Block, Stefan Oswald, Johanna Freyer, Markus Grube, Heyo K Kroemer, Marc Lämmer, Dieter Lütjohann, Monica Venner, Werner Siegmund.   

Abstract

The delivery of clarithromycin (CRL) to its site of action in bronchial/alveolar epithelial cells (EC), bronchial epithelial lining fluid (ELF), and bronchoalveolar lavage cells (BALC) may be influenced by CYP3A4 and the drug transporters, ATP-binding cassette (ABC) B1 and ABCC2 and organic anion-transporting polypeptides (OATPs), which can be modulated and/or up-regulated via the nuclear pregnane X receptor (PXR) by rifampicin (RIF). Therefore, we evaluated the disposition and pulmonary distribution of CLR (7.5 mg/kg b.i.d., 21 days) and expression of ABCB1, ABCC2, OATP1A2, and OATP2B1 in EC and BALC before and after comedication of RIF (10 mg/kg b.i.d., 11 days) in nine healthy foals (41-61 days, 115-159 kg) in which the genetic homology of drug transporters is close to that of their human analogs. After RIF comedication, relative bioavailability of CLR decreased by more than 90%. Concentrations in plasma (29.8 ± 26.3 versus 462 ± 368 ng/ml), ELF (0.69 ± 0.66 versus 9.49 ± 6.12 μg/ml), and BALC (10.2 ± 10.2 μg/ml 264 ± 375 μg/ml; all P < 0.05) were lowered drastically, whereas levels of the metabolite 14-hydroxyclarithromycin were not elevated despite higher 4β-hydroxycholesterol/cholesterol plasma concentration ratio, a surrogate for CYP3A4 induction. In the presence of CLR, ABCC2 and PXR mRNA contents were significantly and coordinately (r(2) = 0.664, P < 0.001) reduced in BALC after RIF. In EC, mRNA expression of OATP1A2 increased but that of OATP2B1 decreased (both P < 0.05). RIF interrupts oral absorption and decreases CRL plasma levels below the minimal inhibitory concentration for eradication of Rhodococcus equi. Evidence that RIF influences the cellular uptake of CLR in bronchial cells and the PXR expression in BALC in the presence of high CLR concentrations exists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21690264     DOI: 10.1124/dmd.111.039206

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; J Gordon Still; Kay Clark; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

2.  Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice.

Authors:  Alexandra J Burton; Steeve Giguère; Londa J Berghaus; Mary K Hondalus
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

3.  Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid.

Authors:  Sara N Salerno; Andrea Edginton; Michael Cohen-Wolkowiez; Christoph P Hornik; Kevin M Watt; Brian D Jamieson; Daniel Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-10-25

4.  Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.

Authors:  Eric A Benson; Michael T Eadon; Zeruesenay Desta; Yunlong Liu; Hai Lin; Kimberly S Burgess; Matthew W Segar; Andrea Gaedigk; Todd C Skaar
Journal:  Front Pharmacol       Date:  2016-04-26       Impact factor: 5.810

5.  In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for Rhodococcus equi disease treatment.

Authors:  Elisa Rampacci; Maria Luisa Marenzoni; Elisabetta Chiaradia; Fabrizio Passamonti; Maurizio Ricci; Marco Pepe; Mauro Coletti; Stefano Giovagnoli
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

Review 6.  Equine Drug Transporters: A Mini-Review and Veterinary Perspective.

Authors:  Brielle Rosa
Journal:  Pharmaceutics       Date:  2020-11-08       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.